A Phase I, Fixed Sequence, Open-label, Study to Assess the Pharmacokinetics of AZD9291 in Healthy Male Volunteers when a Single Oral Dose of AZD9291 80 mg is Administered Alone and in Combination with Omeprazole
AZD9291 tablet dosing, Omeprazole tablet dosing
18 Years - 55 Years
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2017 by AstraZeneca
No locations available
|Experimental: AZD9291 and omeprazole|
Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
Procedure/Surgery: Pharmacokinetic sampling - AZD9291
Blood sampling to measure AZD9291
Drug: AZD9291 tablet dosing
AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
Drug: Omeprazole tablet dosing
Omeprzole taken from Days 1 to 5 in Period 1.
Procedure/Surgery: Pharmacokinetic sampling - AZ5140 and AZ7550
Blood samples to measure levels of AZ5140 and AZ7550